Current through Reg. 50, No. 187; September 24, 2024
A Consultant Pharmacist License Renewal Continuing Education
Program must contain at least three (3) hours of training in any of the
subjects specified below. Duplicate courses are not acceptable.
(1) Drug Therapy - Disease State. Patient
Drug Therapy - management and monitoring.
(a)
Drug, Disease State Information - In-depth disclosure of the drug or
therapeutic class of drugs or disease state including pharmacology, side
effects and interaction.
(b) New
Therapeutic Modalities: Expansion of current drug therapy or
treatment.
(c) Patient Assessment:
Assessment techniques by consultant pharmacist to determine the need and
effectiveness of indicated drug therapy along with identification and
assessment of side effects on patient's well-being.
(d) Pertinent Laboratory Tests.
(e) Therapeutic Dosing.
(2) Administrative Responsibilities.
(a) Update on Administrative
Responsibilities.
1. Legal requirements
including statutes, rules and regulation (Federal and State).
2. The Joint Commission on the Accreditation
of Healthcare Organizations.
3.
Personnel requirements.
4. Health
Insurance Portability and Accountability.
(b) Focus on Consultant Pharmacist Practice
Issues/Concerns.
1. How to get things
accomplished in complex organizations.
2. Key contacts to be effective as a
consultant pharmacist.
3.
Considerations and preparation for site
inspections.
(3) Consultant Pharmacist Facility
Responsibilities. This segment details the requirements in one of the facility
types for which a consultant pharmacist is required. Only one practice setting
may be included in each program.
(a)
Pharmacist-Medication Responsibilities - Assessment mechanism for delivery
system, review procedures and monitoring processes.
(b) Pharmacist-Patient Responsibilities -
Patient assessment, laboratory test monitoring and therapeutic
dosing.
(c) Committee
Responsibilities - Make-up and responsibilities for various facility
committees.
(d) Reporting
requirements.
(4)
Compounding sterile or nonsterile human drugs, or both.
Rulemaking Authority 465.005, 465.012, 465.0125 FS. Law
Implemented 465.012, 465.0125 FS.
New 10-14-91, Formerly 21S-26.302, 61F10-26.302,
59X-26.302, Amended 5-5-05, 7-21-09,
2-2-20.
